• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

ENBREL FDA APPROVED FOR EXPANDED INDICATION

Article

The FDA approved Amgen and Wyeth Pharmaceuticals drug, Enbrel (etanercept), to inhibit the progression of structural damage in patients with active psoriatic arthritis and reduce its signs and symptoms.

Recent Videos
Related Content
Nearly half of FDA-authorized AI tools may be ineffective

Nearly half of FDA-authorized AI tools may be ineffective

Article
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Podcast
Preclinical Medical Students Perform Similarly in Evaluating, Diagnosing Dermatological Diseases in Varying Skin Types

Preclinical Medical Students Perform Similarly in Evaluating, Diagnosing Dermatological Diseases in Varying Skin Types

Article
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Podcast
Study Compares Dose Escalation with Biologics in Psoriasis

Study Compares Dose Escalation with Biologics in Psoriasis

Article
Isotretinoin’s Role in Rosacea Management

Isotretinoin’s Role in Rosacea Management

Article
© 2024 MJH Life Sciences

All rights reserved.